DKSH

DKSH’s 90th Ordinary General Meeting 2023

Retrieved on: 
Thursday, March 16, 2023
Proxy, Executive Committee, Articles of association, Executive Committee of the Palestine Liberation Organization, DKSH, Nomination, CHF, Statutory auditor, Article, Compensation, Holding company, Management

Zurich, Switzerland, March 16, 2023 – DKSH’s shareholders have voted in favor of all motions at the company’s 90th Ordinary General Meeting by a large majority.

Key Points: 
  • Zurich, Switzerland, March 16, 2023 – DKSH’s shareholders have voted in favor of all motions at the company’s 90th Ordinary General Meeting by a large majority.
  • Marco Gadola was re-elected as Chairman, and all current Board members as well as the members of the Nomination and Compensation committee were re-elected for another term of office until completion of the next Ordinary General Meeting.
  • DKSH will distribute CHF 139.6 million to shareholders, with the payout expected to be made as from March 22, 2023.
  • We remain committed to creating value for all stakeholders and look forward to continuing our collaboration in 2023.”

analytica Vietnam 2023: The Largest Gathering of Laboratory Technology, Analysis and Biotechnology Professionals in Southeast Asia

Retrieved on: 
Wednesday, March 15, 2023
ITS, Research, Biomedicine, Thermo Fisher Scientific, Research report, HO, Exhibition, GDP, Foreign direct investment, Biotechnology, SECC, USD, DKSH, Science, General Department of Defence Intelligence, Government, Convention center, Environmental analysis, COVID-19, Knowledge, Growth, Eppendorf, Safety, Science and technology in Asia, ASEAN, LECO Corporation, Merck, Reunion, Clothing, Health care, Medical device, Pharmaceutical industry, Scilab, Shimadzu

The analytica Vietnam 2023 is set to take place from April 19-21, 2023, at the Saigon Exhibition and Convention Center in Ho Chi Minh City, Vietnam.

Key Points: 
  • The analytica Vietnam 2023 is set to take place from April 19-21, 2023, at the Saigon Exhibition and Convention Center in Ho Chi Minh City, Vietnam.
  • HO CHI MINH CITY, VIETNAM, Mar 16, 2023 - (ACN Newswire) - After its three-year hiatus, the seventh edition of analytica Vietnam will be held in Vietnam once again.
  • The show will take place at the Saigon Exhibition and Convention Center (SECC) in Ho Chi Minh City, Vietnam from 19-21 April 2023.
  • "The opportunity to bring back the entire laboratory industry back together at analytica Vietnam proves to be an exciting time for the ASEAN region and our international players.

Brilliant Group and Terra Firma Launch Partnership to Expand Market Support

Retrieved on: 
Tuesday, February 7, 2023
Firma, Plastic, DKSH, Principal, Terra firma, Terra Firma Capital Partners, Partnership, Security printing, Cryptocurrency, Brilliant

RICHMOND, Calif., Feb. 7, 2023 /PRNewswire-PRWeb/ -- Brilliant Group and Terra Firma, a DKSH company, announced today that the companies have entered into a partnership that will allow Terra Firma to sell Brilliant Group's industry-leading fluorescent and phosphorescent pigments.

Key Points: 
  • Fluorescent pigment buyers across the West, South and Eastern U.S. will now benefit from Terra Firma's sales and service expertise.
  • RICHMOND, Calif., Feb. 7, 2023 /PRNewswire-PRWeb/ -- Brilliant Group and Terra Firma, a DKSH company, announced today that the companies have entered into a partnership that will allow Terra Firma to sell Brilliant Group's industry-leading fluorescent and phosphorescent pigments.
  • Terra Firma's industrial customer base will now have convenient access to a complete portfolio of fluorescent and phosphorescent pigment products.
  • Patrick Kelly, Executive Vice President of Principal Development at Terra Firma added, "We are very excited to expand our partnership with Brilliant Group in the United States.

Polycarbonate Films Global Market Report 2022: Growing Adoption of Polycarbonate Films as an Alternative to Conventional Material Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Chemicals, Plastics, Manufacturing, Carbon, UV, DKSH, SWM, Metal, Heat, BPA, Double-Function Form, PLUS, Absorption, Certification, Glass, Polyetherimide, Competition, Multi, Mitsui Chemicals, Car, Health, ID, Electronics, Atmosphere, Hardness, Air conditioning, Optics, Biomass, International Sustainability Alliance, SABIC, ISCC, Wood, Video game, Chemical, Thermoplastic, Teijin, Weathering steel

By 2028, the global market for Polycarbonate Films is expected to grow impressively due to increasing demand from the automobile sector.

Key Points: 
  • By 2028, the global market for Polycarbonate Films is expected to grow impressively due to increasing demand from the automobile sector.
  • Polycarbonate films are becoming increasingly popular due to their superior dielectric strength, reduced moisture absorption, and good dimensional stability.
  • Moreover, biomass-based polycarbonate film gets more preference as it is made from bio-BPA, boosting the polycarbonate films market.
  • In this report, global polycarbonate films market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

DKSH Sells its 25% Stake in Swiss Luxury Watchmaker Bovet

Retrieved on: 
Sunday, January 22, 2023
Sale, DKSH, Security (finance)

Zurich, Switzerland – On December 29, 2022, DKSH Holding AG and Mr. Pascal Raffy, owner of 75% of the share capital of Bovet Fleurier SA, have agreed on the sale of DKSH Holding AG's 25% stake in Bovet Fleurier SA to Mr. Pascal Raffy.

Key Points: 
  • Zurich, Switzerland – On December 29, 2022, DKSH Holding AG and Mr. Pascal Raffy, owner of 75% of the share capital of Bovet Fleurier SA, have agreed on the sale of DKSH Holding AG's 25% stake in Bovet Fleurier SA to Mr. Pascal Raffy.
  • The transaction does not materially affect DKSH's profit and loss statement.

Change in DKSH’s Executive Committee

Retrieved on: 
Sunday, January 22, 2023
Fast, Executive Committee, George Seremetis, National Executive Committee of the Labour Party, FMCG, DKSH, Animal, Management

Zurich, Switzerland – January 3, 2023 – DKSH today announced that Terry Seremetis, Head Business Unit Consumer Goods and member of the Executive Committee, has decided to pursue career opportunities outside of DKSH and that he will leave the company after four years effective June 30, 2023.

Key Points: 
  • Zurich, Switzerland – January 3, 2023 – DKSH today announced that Terry Seremetis, Head Business Unit Consumer Goods and member of the Executive Committee, has decided to pursue career opportunities outside of DKSH and that he will leave the company after four years effective June 30, 2023.
  • A successor will be announced in due course.
  • Stefan P. Butz, CEO, said: “I would like to thank Terry for his strong contributions in transforming the Fast Moving Consumer Goods (FMCG) business.
  • The FMCG business performs well, and the strong leadership team will continue to execute our successful strategy.

Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field

Retrieved on: 
Friday, December 16, 2022
Osteoporosis, Stada Arzneimittel, PIK, Communication, Partnership, Marketing, Offering, Degenerative disease, Sale, Cancer, DKSH, ISK, USD, Biosimilar, Teva Pharmaceuticals, Respiratory disease, COVID-19, Patient, Security (finance), EU, Bond, Alvogen

REYKJAVIK, Iceland, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of approximately US$70 million, at current exchange rates, of subordinated convertible bonds (the “Bonds”), which consists of two tranches, Tranche A and Tranche B, convertible into new fully paid ordinary shares of Alvotech.

Key Points: 
  • Reference is made to the announcement issued earlier today about the completion of a private placement of subordinated convertible bonds.
  • Alvotech intends to use the majority of the net proceeds from the private placement offering to replace a US$50 million unsecured subordinated loan from Alvogen (“Alvogen Facility”) which was announced on November 16, 2022 .
  • In accordance with the Alvogen Facility agreement, associated rights by Alvogen to procure warrants representing up to 4.0% of Alvotech’s ordinary share capital will no longer apply.
  • Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.

Alvotech Completes $59.7 Million Private Placement

Retrieved on: 
Friday, December 16, 2022
Osteoporosis, Stada Arzneimittel, PIK, Communication, Partnership, Marketing, Offering, Degenerative disease, Sale, Cancer, DKSH, ISK, USD, Biosimilar, Teva Pharmaceuticals, Respiratory disease, COVID-19, Patient, Security (finance), EU, Bond, Alvogen

REYKJAVIK, Iceland, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of approximately US$59.7 million, at current exchange rates, of subordinated convertible bonds (the “Bonds”), convertible into new fully paid ordinary shares of Alvotech.

Key Points: 
  • REYKJAVIK, Iceland, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of approximately US$59.7 million, at current exchange rates, of subordinated convertible bonds (the “Bonds”), convertible into new fully paid ordinary shares of Alvotech.
  • Alvotech intends to use the majority of the net proceeds from the private placement offering to replace a US$50 million unsecured subordinated loan from Alvogen (“Alvogen Facility”) which was announced on November 16, 2022 .
  • Alvotech will issue the Bonds in an aggregate principal amount of approximately US$59.7 million, at today’s exchange rate, in the form of subordinated convertible bonds, with a maturity of 36 months and in two tranches.
  • Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide.

Alvotech Completes $59.7 Million Private Placement

Retrieved on: 
Friday, December 16, 2022
Osteoporosis, Stada Arzneimittel, PIK, Communication, Partnership, Marketing, Offering, Degenerative disease, Sale, Cancer, DKSH, ISK, USD, Biosimilar, Teva Pharmaceuticals, Respiratory disease, COVID-19, Patient, Security (finance), EU, Bond, Alvogen

REYKJAVIK, Iceland, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of approximately US$59.7 million, at current exchange rates, of subordinated convertible bonds (the “Bonds”), convertible into new fully paid ordinary shares of Alvotech.

Key Points: 
  • REYKJAVIK, Iceland, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of approximately US$59.7 million, at current exchange rates, of subordinated convertible bonds (the “Bonds”), convertible into new fully paid ordinary shares of Alvotech.
  • Alvotech intends to use the majority of the net proceeds from the private placement offering to replace a US$50 million unsecured subordinated loan from Alvogen (“Alvogen Facility”) which was announced on November 16, 2022 .
  • Alvotech will issue the Bonds in an aggregate principal amount of approximately US$59.7 million, at today’s exchange rate, in the form of subordinated convertible bonds, with a maturity of 36 months and in two tranches.
  • Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide.

Alvotech Shares Start Trading on Nasdaq Iceland Main Market

Retrieved on: 
Thursday, December 8, 2022
Osteoporosis, Marketing, Sale, Post Office Passport Seva Kendra, DKSH, Main–Market Historic District, COVID-19, Stada Arzneimittel, Cancer, Nasdaq Iceland, Main, Biosimilar, Nasdaq First North, Degenerative disease, Prospectus, Respiratory disease, Patient, Communication, Teva Pharmaceuticals, Partnership, EU

Robert Wessman Founder and Executive Chairman will ring the Nasdaq Iceland closing bell at 15:30 GMT on December 8, 2022

Key Points: 
  • Robert Wessman Founder and Executive Chairman will ring the Nasdaq Iceland closing bell at 15:30 GMT on December 8, 2022
    Listing on the Main Market can increase visibility, which may allow the company to appear in both domestic and global indexes
    Alvotech became first dual-listed Icelandic company in the U.S. and Iceland after market debut in June, trading under the symbol “ALVO“
    REYKJAVIK, Iceland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced that trading in its shares will move from the Nasdaq Iceland First North Growth market (“First North”) to the Nasdaq Iceland Main Market (“Main Market”), starting today December 8, 2022.
  • The “ALVO” stock market symbol for Alvotech remains unchanged and trade on the Nasdaq U.S. stock exchange is not affected.  A Main Market listing in Iceland can increase a company’s visibility and, subject to meeting certain conditions, may result in inclusion in Icelandic and international indexes.
  • Alvotech’s shares have been dual listed since June 2022, after being admitted to trading the Nasdaq Stock Market in the U.S. on June 16, 2022 and on First North on June 23, 2022 .
  • On August 12, 2022 , Alvotech’s Board of Directors announced a plan to move the listing from First North to the Main Market and on December 2, 2022 Nasdaq Iceland approved Alvotech’s request to trade its shares on the Main Market.